.png)
.png)
Finance Webinar Series: Introducing the Broker
Register today for the first of our Finance Webinar Series. The first of this series, 'Introducing the Broker', will involve a corporate financier, salesperson and analyst discussing what they do and answering the following questions:
- How practices are changing – impact of MiFID II?
- What should you be asking your broker?
- What should you go back to your board with?
- When should you approach a broker?
- What can they offer?
Speakers
Christine Soden
Christine, a chartered accountant, has some 30 years' experience in the life sciences sector, spanning a broad range of technologies and products from genetic discovery through drug development, branded pharmaceuticals and generics and medical devices. She has served as Chief Financial Officer and Chief Operating Officer and as non-executive director in a range of public and private companies and completed several public and private financing transactions and been instrumental in completing numerous M&A and licensing transactions and business restructurings, both in the UK and internationally. Christine is currently Chief Financial Officer of Acacia Pharma Group plc and a non-executive director of e-therapeutics plc, Fertility Focus Limited and Futurenova Limited. Previously, Christine served as Chief Financial Officer and then non-executive director of AIM-listed Electrical Geodesics, Inc. which was recently acquired by Philips NV, following roles as CFO of Optos plc, BTG plc, Oxagen Limited and Celltech-Chiroscience Group plc having started her life-sciences career as Financial Controller of Medeva plc.
Dr David Cox
David is the Healthcare Specialist Salesperson at Panmure Gordon. Prior to joining Panmure in May 2016, David spent three years at a management and strategy consulting firm with a focus on European pharma companies. David completed multiple projects for a range of private and public pharma companies spanning corporate, commercial and research and development across multiple geographies and therapeutic areas. Before becoming a consultant David has held positions as a medicinal and process chemist at contract research organisations and within Big Pharma. David holds a PhD in Organic Chemistry from the University of Cambridge and an MSci in Chemistry from the University of Bristol.
Max Herrmann
Max joined Stifel in September 2013 as Head of European Healthcare Equity Research. He was also part-time Chief Financial Officer of ReViral Ltd from 2014-2019. Prior to joining Stifel, Max was Chief Financial Officer of Silence Therapeutics plc. He possesses more than 25 years of biotechnology and pharmaceutical industry experience, having held key management positions with leading development-stage companies, as well as establishing several highly rated equity research teams at a number of investment banks. He has also been involved in raising over $700m in funds for biotech companies. Max holds a BSc in Microbiology from the University of Kent and qualified as a Chartered Accountant with Arthur Andersen.
Phil Walker
Phil joined Bryan, Garnier & Co in 2017 as Managing Director UK Healthcare Corporate Finance. Corporate Finance and Equity Capital Market adviser to healthcare/life science and other high growth technology companies for 20 years. Advised on more than 60 successful transactions including IPOs, secondary fundraisings and M&A in the UK, Europe, Israel and the US. Formerly Head of Healthcare Corporate Finance at Zeus Capital, and co-founder of investment banking boutique, Code Securities, which was acquired by Nomura, realising significant returns for investors. Prior to Code, 5 years as a specialist healthcare corporate financier in the WestLB Panmure Life Sciences Group, then Europe’s leading healthcare investment bank. Qualified chartered accountant with Price Waterhouse in 1997.
BIA Annual Supporters
